Coya Therapeutics Secures FDA Fast Track for COYA-302 ALS Therapy
Coya Therapeutics received U.S. FDA Fast Track designation on May 12, 2026 for its lead candidate COYA-302 in amyotrophic lateral sclerosis. The designation grants rolling review and potential priority review benefits, potentially accelerating COYA-302’s clinical development and enhancing Coya’s valuation in the $1.5 billion ALS treatment market.
1. FDA Fast Track Designation for COYA-302
On May 12, 2026, Coya Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track designation to COYA-302 for the treatment of amyotrophic lateral sclerosis. This status enables rolling review of clinical data and eligibility for priority review, aiming to shorten the time to approval.
2. Implications for Clinical Development and Valuation
Fast Track designation often facilitates more frequent interactions with the FDA, allowing Coya to address regulatory questions proactively and potentially streamline Phase II/III trial design. Given the ALS market’s estimated $1.5 billion annual value, this development could materially enhance investor confidence and support Coya’s valuation.